Company intelligence / Profile preview

Ampira Biotechnics

La Jolla, California, United States

Ownership: Private
Development stage: Other

Overview

Ampira Biotechnics is a biotechnology company dedicated to developing next-generation small molecule therapeutics that target the p53 tumor suppressor pathway. The company focuses on restoring the function of mutant p53 proteins, which are prevalent in approximately 50% of all human cancers and have historically been considered undruggable. By utilizing advanced structural biology and screening techniques, Ampira aims to stabilize the wild-type conformation of p53 to trigger apoptosis in cancer cells. Their lead programs are currently in the pre-clinical stage, targeting a variety of solid tumor indications.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ampira Biotechnics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ampira Biotechnics.

Explore the full profile